Background: Conjugated linoleic acid (CLA) has long been recognized to exert protective effects on carcinogenesis in breast, prostate and colon malignancies. Recent data suggests that CLA plays a key role in inhibiting several important survival pathways in breast cancer cell. However, data on effects of CLA in epithelial ovarian carcinoma are lacking and was the focus of this study.

Methods: A2780 and SKOV3 ovarian cancer cell were treated with increasing concentrations of two different isomers of CLA (9:11, 10:12) and effect of CLA on cell viability was determined using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at different time points with and without oxaliplatin. Additionally, effect of CLA isomer 10:12 were evaluated on A2780 ovarian cancer cell apoptosis by flow (Annexin V/PE).

Results: CLA isomer-10:12 significantly affected the ovarian cancer cell viability in a time and dose dependent fashion. Seventy-two to 96h of CLA treatment (isomer 10:12, 7µμ) resulted in ∼50% reduction in cell viability compared to control (p<0.01). A 20 µM dose of the CLA isomer 10:12 resulted in >80% reduction in live cell compared to controls. However, CLA isomer 9:11 had no effect in all doses and time points tested (0.001 µM- 50mM). Additionally, at IC50 dose of oxaliplatin treatment, the addition of CLA, resulted in a substantial reduction (by ∼50%, p<0.05) in percent live cell compared to oxaliplatin monotherapy.

Conclusion: Our data indicate that CLA can significantly hamper the survival of ovarian cancer cell. These findings may have therapeutic implications for ovarian cancer management and needs further exploration.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 683. doi:10.1158/1538-7445.AM2011-683